NORVASC Drug Patent Profile

Which patents cover Norvasc, and when can generic versions of Norvasc launch?

Norvasc is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in NORVASC is amlodipine besylate. There are fifty drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the amlodipine besylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norvasc

A generic version of NORVASC was approved as amlodipine besylate by COREPHARMA on May 23^rd, 2007.

Summary for NORVASC

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for NORVASC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	NORVASC	amlodipine besylate	TABLET;ORAL	019787-001	Jul 31, 1992	AB	RX	Yes	No
Viatris	NORVASC	amlodipine besylate	TABLET;ORAL	019787-002	Jul 31, 1992	AB	RX	Yes	No
Viatris	NORVASC	amlodipine besylate	TABLET;ORAL	019787-003	Jul 31, 1992	AB	RX	Yes	Yes

International Patents for NORVASC

See the table below for patents covering NORVASC around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	22884
Australia	1235183
Australia	540769
Bosnia and Herzegovina	97147
Bosnia and Herzegovina	98207
Bulgaria	60658
Canada	1253865	1,4-DIHYDROPYRIDINES RENFERMANT UN GROUPE BASIQUE AMINE EN 2, AGENTS ANTI-ISCHEMIQUES ET ANTIHYPERTENSEURS (1,4-DIHYDRO HAVING A BASIC AMINO-CONTAINING GROUP ATTACHED TO THE 2-POSITION AS ANTI-ISCHAEMIC AND ANTIHYPERTENSIVE AGENTS)

Supplementary Protection Certificates for NORVASC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0443983	C300445	Netherlands		PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
1003503	05C0048	France		PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
1507558	2012/018	Ireland		PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
0503785	CA 2011 00026	Denmark		PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
1507558	C300528	Netherlands		PRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705
1507558	12C0033	France		PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: CH - 6167801 20110705
0502314	C300478	Netherlands		PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007

Norvasc (Amlodipine Besylate) Investment Scenario and Fundamentals Analysis (Patent, Regulatory, and Market Outlook)

Last updated: July 26, 2026

Norvasc (amlodipine besylate) is an extensively genericized, low-innovation-cost cardiovascular product with limited near-term patent-driven upside and persistent price pressure. Core investment relevance is not “new exclusivity,” but how supply contracts, line-of-business share in hypertension and angina, and channel concentration translate into stable volume at low gross margins.

Why does Norvasc generate stable demand despite generic competition?

Featured answer: Norvasc’s durability comes from broad guideline use in hypertension and angina, high prescriber familiarity, and clinician trust in predictable blood-pressure lowering.

Clinical positioning and utilization drivers

• Drug class: dihydropyridine calcium channel blocker (CCB)
• Common indications (US label): hypertension; chronic stable angina; vasospastic angina
• Use pattern: long-term maintenance therapy in hypertension and recurring angina regimens

Business fundamentals: the “volume beats pricing” model

• Amlodipine is typically treated as a core chronic therapy. That supports:
  • repeat prescriptions
  • large, entrenched pharmacy footprint
  • rapid switching to lowest-cost multiples once payer formularies move
• Margins generally track:
  • generic benchmark pricing
  • PBM rebates and formulary placement
  • manufacturing scale and delivery reliability

Channel and payer structure

• Retail and long-term care are key.
• PBMs commonly favor lowest net-cost generics, making brand economics reliant on:
  • maintaining preferred formulary status (less relevant as generics dominate)
  • brand-only contracts for specific accounts (rare for top-volume generics)

What patents protect Norvasc, and when do they expire?

Featured answer: The active ingredient is amlodipine besylate, which long predates current investable patent terms; most “base” composition and method claims are expired or close to expired in major markets. Residual value, if any, usually comes from later-life line extensions (formulation, dosing forms, or combinations) rather than the amlodipine molecule itself.

Patent estate reality check (investment lens)

For a molecule this mature:

• New entrants are largely independent generic manufacturers rather than challengers to fresh primary patents.
• Residual exclusivity typically affects:
  • specific dosage forms (eg, distinct strengths, scoring/packaging, patient-friendly delivery)
  • fixed-dose combinations
  • country-specific process/formulation grants

What to model in an investment case

• Patent-driven upside is small unless you have exposure to:
  • a still-protected combination product
  • a protected delivery system or process patent with nontrivial manufacturing/IP barriers
• Otherwise, returns are driven by:
  • procurement strategy
  • manufacturing cost curve
  • contract manufacturing economics
  • distribution scale

Jurisdiction scope investors should assume

• US: Orange Book coverage is expected to be sparse for the core molecule by now; check listing history for each specific dosage form/strength.
• EU and UK: similar maturity with possible process/formulation pockets, but commercial relevance is typically limited for top-volume, low-cost APIs.

What is the Orange Book status of Norvasc (amlodipine) and its key generics?

Featured answer: Norvasc’s US market exposure is dominated by generic equivalents; the Orange Book role is mostly to identify any remaining-listed patents tied to specific dosage forms, not to support durable brand exclusivity.

How Orange Book status changes the risk profile

• If no listed patents remain for a given dosage form, generic entry risk for that specific presentation is low because entry is already normalized.
• If a later-life patent remains, it can affect:
  • specific strengths
  • specific manufacturer-to-manufacturer supply
  • litigation/section carve-outs for launch designs

Investor takeaway

This is a “structure and execution” investment, not a “patent watch” investment, unless you are targeting:

• a specific protected combination
• a protected formulation line
• a protected dosing form

How do Paragraph IV challenges affect Norvasc’s market dynamics?

Featured answer: For older, widely genericized molecules, Paragraph IV dynamics are less about first generics and more about margin capture via incremental price reductions and supply chain competition.

What matters more than first-wave litigation

• Whether manufacturers remain active in filing and settling for subsequent label presentations
• Whether any remaining Orange Book patents are litigated for specific strengths or dosage forms
• Settlement terms that lock in “staggered launch” timing across companies (rarely value-creating at this stage unless there is a still-relevant patent)

Investment lens

• Treat generic market entry as a continuing commodity risk rather than an event-driven upside.
• Model price declines by historical benchmarking of amlodipine generics rather than expecting patent settlements to sustain high prices.

What generic entry risks exist for Norvasc?

Featured answer: Generic entry risk is structural and ongoing through incremental competition, not a single-date event.

Key risk vectors

• New entrants can reduce benchmark pricing.
• Existing suppliers can expand capacity, increasing competitive pressure.
• PBM contracting can rapidly re-price a category once a supplier loses preferred status.

Counterweights that reduce risk

• Chronic therapy switching friction is modest but payer switching is quick.
• Supply chain resilience and cost-of-goods leadership protect some incumbents from catastrophic share loss.

How does Norvasc compare with other cardiovascular generics for investment attractiveness?

Featured answer: Compared with newer branded CV drugs, Norvasc is lower risk on demand but lower upside on pricing, with returns tied to operating efficiency.

Relative comparison: what investors should score

• Demand stability: high
• Growth: low (market is mature)
• Pricing upside: low
• Volatility: moderate, driven by commodity pricing and PBM contract renewals
• IP upside: limited unless tied to protected combinations/delivery systems

Where Norvasc can still outperform

• If an investor is underwriting a supply portfolio with:
  • best-cost API access
  • strong contract manufacturing scale
  • durable customer relationships in retail or institutional channels

What is the revenue exposure to Norvasc across the US portfolio?

Featured answer: Revenue is exposed primarily through genericized volume at competitive net pricing, not through brand premium.

Revenue model you should use

• Revenue = (unit volume) × (net price)
• Unit volume is stable; net price is the key swing factor.
• Net price depends on:
  • PBM reimbursement benchmarks
  • wholesaler inventory dynamics
  • competitive bid behavior

Portfolio implications

• Norvasc becomes a “base layer” revenue driver.
• The upside case depends on:
  • capture of additional units via formulary status
  • lowering COGS
  • avoiding supply disruptions and recalls

What formulation patents or line extensions could still matter?

Featured answer: At this maturity level, “molecule patents” are often expired; only later-life patents tied to specific dosage forms or combination products can affect commercial advantage.

Possible categories of still-relevant IP

• Fixed-dose combinations (amlodipine with other agents)
• Distinct dosage strengths or specific manufacturing processes
• Patient adherence enhancements (release profile changes are less common for amlodipine, but combinations may still have formulation protection)

How this changes investability

• If your investment thesis includes a protected combination, then you must underwrite:
  • remaining term by jurisdiction
  • likelihood of generic substitution
  • manufacturing and regulatory pathway feasibility
• If your thesis is the standalone molecule only, then it is primarily an execution play.

What manufacturing and regulatory barriers affect Norvasc generics?

Featured answer: Barriers are mostly operational, not IP driven, because regulatory pathways for generic amlodipine are well established.

Typical friction points

• API sourcing consistency and impurity control
• bioequivalence and formulation equivalence validation
• batch release and stability
• compliance and inspection risk

Investment relevance

• If you control manufacturing or have contract manufacturing with proven quality, you reduce:
  • supply interruptions
  • margin shocks from quality events
• These factors matter more than patent strategy.

How does FDA status influence Norvasc commercialization risk?

Featured answer: FDA status mostly influences speed to market and supply continuity; for an established generic landscape, the bigger risk is pricing and contracting rather than regulatory blocks.

Regulatory pathway assumptions

• Generic products typically proceed under ANDA structures where bioequivalence is established for dosage forms.
• Safety and labeling changes can still occur, but they rarely create durable exclusivity.

Investor lens

• Monitor enforcement actions and recurring quality signals.
• Track filings that might alter competitive supply intensity.

What are the most realistic generic launch scenarios for Norvasc?

Featured answer: Launch scenarios should be modeled as ongoing incremental competition that depresses net price rather than a sudden brand-to-generic cliff.

Scenario framework (commodity logic)

1. Incremental entrants increase supply and lower net pricing gradually.
2. PBM renegotiations re-anchor benchmarks, shifting share among suppliers.
3. Capacity expansions by major generic manufacturers can create temporary oversupply and further price compression.
4. Supply disruptions by one supplier can temporarily restore pricing for remaining players but are not durable.

How does Norvasc’s competitive landscape affect pricing and margins?

Featured answer: The competitive landscape is dense, and pricing is anchored to generic benchmarks with limited room for sustained margin expansion without cost leadership.

Competitive categories

• Large diversified generics with cost scale
• Specialty generics focused on contract formulas and delivery reliability
• Private label/authorized distributors depending on wholesaler dynamics

What to monitor

• Market share shifts at the PBM level
• Average selling price trends versus benchmark
• Wholesale inventory levels and lead times
• Spec impurity trends that can trigger production pauses

Key Takeaways

• Norvasc is a mature cardiovascular generic with stable demand and structurally low upside on brand premium.
• Patent-driven exclusivity is not the primary value lever; residual IP only matters if you have exposure to specific protected combinations or dosage forms.
• Investment returns are driven by execution: contract positioning, cost of goods, manufacturing reliability, and inventory management.
• Treat generic entry risk as continuous pricing pressure rather than event-driven disruption.

FAQs

1. Is Norvasc still a brand product, or is it mostly sold as generics now?
2. Do fixed-dose combination products containing amlodipine offer better patent or reimbursement visibility than standalone amlodipine?
3. What margins matter most for investing in amlodipine products: net price, rebate structure, or manufacturing scale?
4. What FDA or quality events most commonly disrupt generic amlodipine supply?
5. How do PBM formulary changes typically affect generic amlodipine pricing and volume?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA. Guidance for Industry: Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms. https://www.fda.gov/
3. FDA. Drug Approval Reports and Labeling Information (access via Drugs@FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
4. FDA. Drugs@FDA: Norvasc (amlodipine besylate) and related applications (search portal). https://www.accessdata.fda.gov/scripts/cder/daf/